gastroesophageal reflux disease (GERD)
Conditions
Interventions
None listed
Sponsors
GERD Society
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: To be eligible for this study, patients must have undergone endoscopy between August 2005 and July 2010, meet all of the following inclusion criteria, and not meet any of the key exclusion criteria: - Patients of both sexes aged 20 years and above - Patients who received eight-week or longer treatment with any of the designated PPIs (i.e., drugs surveyed) of omeprazole, lansoprazole, or rabeprazole - Patients with endoscopically confirmed Grade A or worse reflux esophagitis according to the LA classification within four weeks before PPI therapy - Patients who underwent endoscopy after at least eight weeks of PPI therapy, for whom records are available on findings according to the LA classification. The endoscopic findings must have been obtained from endoscopy conducted during PPI therapy or within four weeks after the end of PPI therapy.
Exclusion criteria
Exclusion criteria: 1) Patients who had a history of gastrointestinal resection or vagotomy 2) Patients who had a concurrent malignant lesion 3) Patients who had a prior or current history of any of the following diseases: - Esophageal stricture - Eosinophilic reflux esophagitis - Esophageal achalasia - Malabsorption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Esophageal endoscopic findings after at least eight weeks of treatment with any of the drugs surveyed | — |
Secondary
| Measure | Time frame |
|---|---|
| Factors that may affect cure of lesions (e.g., sex, age, BMI, duration of disease, LA grade, acid reflux-related symptoms, H. pylori, PPI dose) | — |
Countries
Japan
Outcome results
None listed